These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28387939)

  • 1. Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
    Niu J; Scheuerell C; Mehrotra S; Karan S; Puhalla S; Kiesel BF; Ji J; Chu E; Gopalakrishnan M; Ivaturi V; Gobburu J; Beumer JH
    J Clin Pharmacol; 2017 Aug; 57(8):977-987. PubMed ID: 28387939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies.
    Salem AH; Giranda VL; Mostafa NM
    Clin Pharmacokinet; 2014 May; 53(5):479-88. PubMed ID: 24452810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients.
    Stodtmann S; Nuthalapati S; Eckert D; Kasichayanula S; Joshi R; Bach BA; Mensing S; Menon R; Xiong H
    J Clin Pharmacol; 2021 Sep; 61(9):1195-1205. PubMed ID: 33894017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
    Mittapalli RK; Nuthalapati S; Shepherd SP; Xiong H
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):587-594. PubMed ID: 28247011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
    LoRusso PM; Li J; Burger A; Heilbrun LK; Sausville EA; Boerner SA; Smith D; Pilat MJ; Zhang J; Tolaney SM; Cleary JM; Chen AP; Rubinstein L; Boerner JL; Bowditch A; Cai D; Bell T; Wolanski A; Marrero AM; Zhang Y; Ji J; Ferry-Galow K; Kinders RJ; Parchment RE; Shapiro GI
    Clin Cancer Res; 2016 Jul; 22(13):3227-37. PubMed ID: 26842236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies.
    Mehrotra S; Gopalakrishnan M; Gobburu J; Greer JM; Piekarz R; Karp JE; Pratz K; Rudek MA
    Br J Clin Pharmacol; 2017 Aug; 83(8):1688-1700. PubMed ID: 28156017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.
    Su JM; Thompson P; Adesina A; Li XN; Kilburn L; Onar-Thomas A; Kocak M; Chyla B; McKeegan E; Warren KE; Goldman S; Pollack IF; Fouladi M; Chen A; Giranda V; Boyett J; Kun L; Blaney SM
    Neuro Oncol; 2014 Dec; 16(12):1661-8. PubMed ID: 24908656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
    Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline
    Somlo G; Frankel PH; Arun BK; Ma CX; Garcia AA; Cigler T; Cream LV; Harvey HA; Sparano JA; Nanda R; Chew HK; Moynihan TJ; Vahdat LT; Goetz MP; Beumer JH; Hurria A; Mortimer J; Piekarz R; Sand S; Herzog J; Van Tongeren LR; Ferry-Galow KV; Chen AP; Ruel C; Newman EM; Gandara DR; Weitzel JN
    Clin Cancer Res; 2017 Aug; 23(15):4066-4076. PubMed ID: 28356425
    [No Abstract]   [Full Text] [Related]  

  • 10. Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics.
    Li J; Kim S; Sha X; Wiegand R; Wu J; LoRusso P
    Clin Cancer Res; 2014 Aug; 20(15):3931-44. PubMed ID: 24947923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells.
    Ji J; Kinders RJ; Zhang Y; Rubinstein L; Kummar S; Parchment RE; Tomaszewski JE; Doroshow JH
    PLoS One; 2011; 6(10):e26152. PubMed ID: 22028822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
    Manzo J; Puhalla S; Pahuja S; Ding F; Lin Y; Appleman L; Tawbi H; Stoller R; Lee JJ; Diergaarde B; Kiesel BF; Yu J; Tan AR; Belani CP; Chew H; Garcia AA; Morgan RJ; Wahner Hendrickson AE; Visscher DW; Hurley RM; Kaufmann SH; Swisher EM; Oesterreich S; Katz T; Ji J; Zhang Y; Parchment RE; Chen A; Duan W; Giranda V; Shepherd SP; Ivy SP; Chu E; Beumer JH;
    Cancer Chemother Pharmacol; 2022 May; 89(5):721-735. PubMed ID: 35435472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
    Singh R; Mehrotra S; Gopalakrishnan M; Gojo I; Karp JE; Greer JM; Chen A; Piekarz R; Kiesel BF; Gobburu J; Rudek MA; Beumer JH;
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):319-328. PubMed ID: 30456480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients.
    Nuthalapati S; Stodtmann S; Shepherd SP; Ratajczak CK; Mensing S; Menon R; Xiong H
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):977-986. PubMed ID: 31468137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
    Rodler ET; Kurland BF; Griffin M; Gralow JR; Porter P; Yeh RF; Gadi VK; Guenthoer J; Beumer JH; Korde L; Strychor S; Kiesel BF; Linden HM; Thompson JA; Swisher E; Chai X; Shepherd S; Giranda V; Specht JM
    Clin Cancer Res; 2016 Jun; 22(12):2855-64. PubMed ID: 26801247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
    Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
    Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.
    Wahner Hendrickson AE; Menefee ME; Hartmann LC; Long HJ; Northfelt DW; Reid JM; Boakye-Agyeman F; Kayode O; Flatten KS; Harrell MI; Swisher EM; Poirier GG; Satele D; Allred J; Lensing JL; Chen A; Ji J; Zang Y; Erlichman C; Haluska P; Kaufmann SH
    Clin Cancer Res; 2018 Feb; 24(4):744-752. PubMed ID: 29138343
    [No Abstract]   [Full Text] [Related]  

  • 18. A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).
    Mizugaki H; Yamamoto N; Nokihara H; Fujiwara Y; Horinouchi H; Kanda S; Kitazono S; Yagishita S; Xiong H; Qian J; Hashiba H; Shepherd SP; Giranda V; Tamura T
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1063-72. PubMed ID: 26433581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
    Anampa J; Chen A; Wright J; Patel M; Pellegrino C; Fehn K; Sparano JA; Andreopoulou E
    Clin Breast Cancer; 2018 Feb; 18(1):e135-e142. PubMed ID: 28935542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.
    Tan AR; Chan N; Kiesel BF; Stein MN; Moss RA; Malhotra J; Aisner J; Shah M; Gounder M; Lin H; Kane MP; Lin Y; Ji J; Chen A; Beumer JH; Mehnert JM
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):49-58. PubMed ID: 34669023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.